Apyx Medical (NASDAQ:APYX – Get Free Report) and Stagezero Life Sciences (OTCMKTS:SZLSF – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Profitability
This table compares Apyx Medical and Stagezero Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Apyx Medical | -16.40% | -88.47% | -14.94% |
| Stagezero Life Sciences | N/A | N/A | N/A |
Valuation & Earnings
This table compares Apyx Medical and Stagezero Life Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apyx Medical | $55.90 million | 2.90 | -$11.21 million | ($0.22) | -17.59 |
| Stagezero Life Sciences | N/A | N/A | N/A | ($0.01) | -0.51 |
Stagezero Life Sciences has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Apyx Medical and Stagezero Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apyx Medical | 1 | 1 | 3 | 1 | 2.67 |
| Stagezero Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
Apyx Medical presently has a consensus target price of $6.50, indicating a potential upside of 67.96%. Given Apyx Medical’s stronger consensus rating and higher possible upside, research analysts clearly believe Apyx Medical is more favorable than Stagezero Life Sciences.
Risk & Volatility
Apyx Medical has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Stagezero Life Sciences has a beta of -4.22, meaning that its share price is 522% less volatile than the S&P 500.
Institutional & Insider Ownership
55.3% of Apyx Medical shares are held by institutional investors. 15.2% of Apyx Medical shares are held by company insiders. Comparatively, 2.5% of Stagezero Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Apyx Medical beats Stagezero Life Sciences on 8 of the 13 factors compared between the two stocks.
About Apyx Medical
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
About Stagezero Life Sciences
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
